ASP9853, an inhibitor of inducible nitric oxide synthase dimerization, in combination with docetaxel: preclinical investigation and a Phase I study in advanced solid tumors

Pharmacokinetics, dynamics and toxicity of docetaxel: Why the Japanese dose differs from the Western dose

(2015) Hirotsugu Kenmotsu et al.   CANCER SCIENCE

Molecular Pathways: Inflammation-Associated Nitric-Oxide Production as a Cancer-Supporting Redox Mechanism and a Potential Therapeutic Target

(2013) E. A. Grimm et al.   CLINICAL CANCER RESEARCH

iNOS-selective inhibitors for cancer prevention: promise and progress

(2012) Naveena B Janakiram et al.   Future Medicinal Chemistry

Tumor-Expressed Inducible Nitric Oxide Synthase Controls Induction of Functional Myeloid-Derived Suppressor Cells through Modulation of Vascular Endothelial Growth Factor Release

(2012) P. Jayaraman et al.   JOURNAL OF IMMUNOLOGY

Nitric oxide and redox mechanisms in the immune response

(2011) David A. Wink et al.   JOURNAL OF LEUKOCYTE BIOLOGY

Targeted Inhibition of Inducible Nitric Oxide Synthase Inhibits Growth of Human Melanoma In vivo and Synergizes with Chemotherapy

(2010) A. G. Sikora et al.   CLINICAL CANCER RESEARCH

Molecular control of blood flow and angiogenesis: role of nitric oxide

(2009) W. C. SESSA   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

NO Signaling Confers Cytoprotectivity through the Survivin Network in Ovarian Carcinomas

(2008) K. Engels et al.   CANCER RESEARCH

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER

Inducible NO synthase confers chemoresistance in head and neck cancer by modulating survivin

(2008) Verena Fetz et al.   INTERNATIONAL JOURNAL OF CANCER

Docetaxel Plus Prednisone or Mitoxantrone Plus Prednisone for Advanced Prostate Cancer: Updated Survival in the TAX 327 Study

(2008) Dominik R. Berthold et al.   JOURNAL OF CLINICAL ONCOLOGY